Takeda Pharmaceutical (TAK) EBT Margin (2017 - 2026)

Takeda Pharmaceutical's EBT Margin history runs 10 years deep, the most recent figure standing at 4.79% for Q1 2026.

• In Q1 2026, EBT Margin fell 3398.0% year-over-year to 4.79%; the TTM figure through Mar 2026 stood at 19.3% (down 289.0% YoY), while the FY2026 annual figure was 5.77%, up 195.0% from the prior year.
• EBT Margin was 4.79% for Q1 2026 at Takeda Pharmaceutical, down from 15.19% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 29.19% in Q1 2025 to a low of 4.79% in Q1 2026.
• Historically, EBT Margin has averaged 15.67% across 5 years, with a median of 15.19% in 2025.
• The sharpest annual moves came in 2025 and 2026: EBT Margin soared 3371 bps in 2025, then sank 3398 bps in 2026.
• A 5-year view of EBT Margin shows it stood at 9.77% in 2022, then soared by 104 bps to 19.97% in 2023, then dropped by 26 bps to 14.85% in 2024, then grew by 2 bps to 15.19% in 2025, then tumbled by 132 bps to 4.79% in 2026.
• The last three EBT Margin figures came in at 4.79% (Q1 2026), 15.19% (Q4 2025), and 25.55% (Q3 2025), per Business Quant data.